Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray

• Status: Recruiting
• Trial end date: 2022-04-11
• Target enrollment: 0
• Participant gender: All

Summary

Pragmatic clinical trial of an add-on therapy regarding the use of edupression.com® - a licensed computer based self-help program - on patients with therapy-resistant depression receiving esketamine nasal spray

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lukas Pezawas
• Treatments: Esketamine

Criteria

Inclusion Criteria:

• Age 18 or older

• Initial MADRS-Score of 22 or above

• Diagnosis of a therapy-resistant depression following the definition of the European Medicines Agency (EMA) - absence of remission after two or more guideline-oriented therapies

• Patients assigned to treatment with nasal esketamine spray Spravato®

• Signed informed consent

• Native German speaker

• Basic knowledge in using computers/smartphones operationalized as daily use of at least two devices (such as tablets, computers, smartphones etc)

Exclusion Criteria:

• Contraindication regarding the use of Spravato®

• Diagnosis of one of the following psychiatric comorbidities: substance abuse, schizoaffective disorders, schizophrenia, bipolar disorder, organic disorders diagnosed via Mini International Neuropsychiatric Interview (MINI)